
    
      This is a 48 week interventional study evaluating the effect of Dual therapy ( Treprostinil
      inhalations and Tadalafil) versus Mono therapy (Tadalafil). The impact of the therapy on
      cardiovascular parameters in PAH measured at 24 weeks and event free survival outcome at 48
      weeks.
    
  